Lab Dashboard
Real-time laboratory operations overview for BioNova Research
Active Experiments
8
+2 this week
Samples in Process
142
94% on schedule
Equipment Online
23/25
1 in maintenance
Compliance Score
99.2%
CAP audit passed
Sample Processing Pipeline
142 samples activeReceived
38
→
38
Processing
52
→
52
QC Review
31
→
31
Complete
21
21
Recent Activity
Sample BN-2026-0891 passed QC - CBC panel complete
2 min ago
Experiment EXP-047 reached 72h incubation checkpoint
14 min ago
PCR Cycler #3 calibration verified - PASS
28 min ago
Dr. Chen submitted protocol revision for CRISPR-Cas9 knock-in
1 hr ago
Reagent alert: Taq polymerase stock below reorder threshold
2 hr ago
Equipment Status
PCR Cycler #1
Centrifuge A
NGS Sequencer
Autoclave #2
-80C Freezer
Mass Spec
LIMS - Laboratory Information Management
Track samples from accessioning through final reporting with full chain of custody
Received
38
→
38
Processing
52
→
52
QC Review
31
→
31
Complete
21
21
Sample Tracking
| Sample ID | Type | Patient/Source | Test Panel | Status | Analyst | Results |
|---|
Experiment Tracker
Active research experiments with protocol steps, reagent usage, and environmental logs
Gene Sequence Analysis
DNA sequence viewer with base composition analysis and protein translation
Sequence Viewer - BRCA1 Exon 11 Fragment
Legend:
A = Adenine
T = Thymine
G = Guanine
C = Cytosine
Base Composition
Protein Translation (Reading Frame 1)
Standard Codon Table (Selected)
Clinical Trials Management
Track trial phases, patient enrollment, adverse events, and FDA submission milestones
Active Trials
3
Phase I, II, III
Total Enrolled
1,247
+89 this month
Adverse Events
12
3 serious (SAE)
Trial Portfolio
| Trial ID | Drug/Therapy | Phase | Enrolled | Target | Adverse Events | Status |
|---|---|---|---|---|---|---|
| NCT-2026-0041 | BNV-301 (Anti-PD-L1 mAb) | Phase I | 47 | 60 | 2 (0 SAE) | Enrolling |
| NCT-2025-1187 | BNV-205 (CAR-T CD19) | Phase II | 312 | 400 | 7 (2 SAE) | Enrolling |
| NCT-2024-0893 | BNV-118 (mRNA Vaccine) | Phase III | 888 | 1000 | 3 (1 SAE) | Enrolling |
FDA Submission Timeline
IND Application - BNV-301
Approved - Oct 2025
Phase I Complete - BNV-205
Completed - Jun 2025
Interim Analysis - BNV-118 Phase III
Scheduled - Apr 2026
BLA Submission - BNV-118
Target - Q4 2026
PDUFA Date - BNV-118
Projected - Q2 2027
Adverse Event Log
| Date | Trial | Grade | Event |
|---|---|---|---|
| Feb 6 | BNV-205 | 3 (SAE) | Cytokine release syndrome |
| Feb 3 | BNV-118 | 2 | Injection site reaction |
| Jan 29 | BNV-301 | 1 | Fatigue, Grade 1 |
| Jan 22 | BNV-205 | 3 (SAE) | Neurotoxicity (ICANS) |
| Jan 18 | BNV-118 | 1 | Headache, mild |